Historical Valuation
Esperion Therapeutics Inc (ESPR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.83 is considered Undervalued compared with the five-year average of -1.73. The fair price of Esperion Therapeutics Inc (ESPR) is between 55.33 to 63.86 according to relative valuation methord. Compared to the current price of 3.88 USD , Esperion Therapeutics Inc is Undervalued By 92.99%.
Relative Value
Fair Zone
55.33-63.86
Current Price：3.88
92.99%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Esperion Therapeutics Inc (ESPR) has a current Price-to-Book (P/B) ratio of -1.69. Compared to its 3-year average P/B ratio of -0.89 , the current P/B ratio is approximately 90.07% higher. Relative to its 5-year average P/B ratio of -1.41, the current P/B ratio is about 20.02% higher. Esperion Therapeutics Inc (ESPR) has a Forward Free Cash Flow (FCF) yield of approximately -10.68%. Compared to its 3-year average FCF yield of -48.53%, the current FCF yield is approximately -77.99% lower. Relative to its 5-year average FCF yield of -51.85% , the current FCF yield is about -79.40% lower.
P/B
Median3y
-0.89
Median5y
-1.41
FCF Yield
Median3y
-48.53
Median5y
-51.85
Competitors Valuation Multiple
AI Analysis for ESPR
The average P/S ratio for ESPR competitors is 111.68, providing a benchmark for relative valuation. Esperion Therapeutics Inc Corp (ESPR.O) exhibits a P/S ratio of 1.83, which is -98.36% above the industry average. Given its robust revenue growth of 69.10%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ESPR
1Y
3Y
5Y
Market capitalization of ESPR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ESPR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ESPR currently overvalued or undervalued?
Esperion Therapeutics Inc (ESPR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.83 is considered Undervalued compared with the five-year average of -1.73. The fair price of Esperion Therapeutics Inc (ESPR) is between 55.33 to 63.86 according to relative valuation methord. Compared to the current price of 3.88 USD , Esperion Therapeutics Inc is Undervalued By 92.99% .
What is Esperion Therapeutics Inc (ESPR) fair value?
ESPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Esperion Therapeutics Inc (ESPR) is between 55.33 to 63.86 according to relative valuation methord.
How does ESPR's valuation metrics compare to the industry average?
The average P/S ratio for ESPR's competitors is 111.68, providing a benchmark for relative valuation. Esperion Therapeutics Inc Corp (ESPR) exhibits a P/S ratio of 1.83, which is -98.36% above the industry average. Given its robust revenue growth of 69.10%, this premium appears sustainable.
What is the current P/B ratio for Esperion Therapeutics Inc (ESPR) as of Jan 09 2026?
As of Jan 09 2026, Esperion Therapeutics Inc (ESPR) has a P/B ratio of -1.69. This indicates that the market values ESPR at -1.69 times its book value.
What is the current FCF Yield for Esperion Therapeutics Inc (ESPR) as of Jan 09 2026?
As of Jan 09 2026, Esperion Therapeutics Inc (ESPR) has a FCF Yield of -10.68%. This means that for every dollar of Esperion Therapeutics Inc’s market capitalization, the company generates -10.68 cents in free cash flow.
What is the current Forward P/E ratio for Esperion Therapeutics Inc (ESPR) as of Jan 09 2026?
As of Jan 09 2026, Esperion Therapeutics Inc (ESPR) has a Forward P/E ratio of 12.29. This means the market is willing to pay $12.29 for every dollar of Esperion Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Esperion Therapeutics Inc (ESPR) as of Jan 09 2026?
As of Jan 09 2026, Esperion Therapeutics Inc (ESPR) has a Forward P/S ratio of 1.83. This means the market is valuing ESPR at $1.83 for every dollar of expected revenue over the next 12 months.